Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 43 for:    "Bronchial Disease" | "Azithromycin"
Previous Study | Return to List | Next Study

Efficacy of Azithromycin in Treatment of Bronchiectasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02107274
Recruitment Status : Completed
First Posted : April 8, 2014
Results First Posted : July 9, 2014
Last Update Posted : July 18, 2014
Sponsor:
Information provided by (Responsible Party):
ALBERT IRUTHIARAJ L. ANTHONY, Ministry of Health, Malaysia

Brief Summary:
Bronchiectasis is a chronic lung condition characterised primarily by dilatation of the airways. Only a small number of clinical studies have been conducted investigating the use of macrolides to treat non-cystic fibrosis bronchiectasis. The purpose of this study is to determine the efficacy of 12 weeks treatment with azithromycin in adult patients with non-cystic fibrosis bronchiectasis.

Condition or disease Intervention/treatment Phase
Bronchiectasis Drug: Azithromycin Drug: Placebo for Azithromycin Phase 4

Detailed Description:

Previous studies of various macrolides with small sample sizes have reported some benefit with the reduction of sputum volume in bronchiectasis patients. However, macrolide therapy could not yet be confidently used to treat bronchiectasis, given the diffuse nature of these findings. These studies have had a wide range of hypotheses, and have not necessarily focused on the anti-inflammatory effects of macrolides. Furthermore, these studies are few in number, and not all have been placebo-controlled or double-blinded. This, combined with the small sample sizes used, limits the reliability of these results. This study aims to expand on these limited published findings by investigating a larger sample population with different endpoints. Sputum volume and quality of life have been selected as important variables to aid in assessing efficacy.

This study aims to be independent of previous studies in a number of ways. This is the only study of bronchiectasis patients to formally investigate quality of life after treatment with a macrolide, and the potential carryover effect of azithromycin therapy. This study will also expand on the findings of previous studies of macrolides in bronchiectasis by incorporating a larger sample size into the trial.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 78 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy of Azithromycin in Treatment of Bronchiectasis
Study Start Date : November 2011
Actual Primary Completion Date : December 2013
Actual Study Completion Date : December 2013

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Azithromycin and Placebo for Azithromycin
Patients randomised to the treatment arm are to receive 1000 mg of azithromycin once a week for 12 weeks followed by placebo for azithromycin once weekly for another 12 weeks
Drug: Azithromycin
Azithromycin (C38H72N2O12 MW 749) is a 15-membered azalide, a subclass of macrolide antibiotics
Other Name: Zithromax 250 mg tablet

Placebo Comparator: Placebo for Azithromycin
In Part One of the study participants will be randomised to receive 12 weeks of either placebo or azithromycin in a 1:1 ratio in a double-blinded fashion. After 12 weeks, in Part Two of the study, all participants will receive placebo in a double-blinded fashion for an additional 12 weeks.
Drug: Placebo for Azithromycin
In Part One of the study participants will be randomised to receive 12 weeks of either placebo or azithromycin in a 1:1 ratio in a double-blinded fashion. After 12 weeks, in Part Two of the study, all participants will receive placebo in a double-blinded fashion for an additional 12 weeks.




Primary Outcome Measures :
  1. 24 Hour Sputum Volume [ Time Frame: Visit 3 (Baseline); Visit 6 (Week 12); Visit 8 (Week 24) ]
    Each participant must be instructed and enabled to collect 24 hour sputum volumes over the 24 hours prior to visits 3, 6 and 8, inclusive. As this is the primary endpoint of the study, it is critical that 24 hour sputum volumes are measured and recorded accurately, observing the following protocol: The subject should be given a sterile jar to collect the sputum, which has been weighed previously for convenience. Each jar will be labelled with subject name, start and finish time/date The collection should commence on rising in the morning and complete 24 hours later. Ensure that the sputum sample has minimal saliva in the collection Instruct subject to collect all sputum produced spontaneously or after coughing over a single daytime 24 hour period. The sample should come from the lungs and should not be salivary. Encourage subject not to swallow sputum, but to collect. Each 24 hour collection period should be as similar as possible in terms of physiotherapy and exercise regimens


Secondary Outcome Measures :
  1. Health Status: St George's Respiratory Questionnaire Score [ Time Frame: Visit 3 (Baseline); Visit 6 (Week 12); Visit 8 (Week 24) ]
    The St. George Respiratory Questionnaire is to be administered at visits 3, 6 and 8 inclusive. It should be administered in a quiet room where the participant can answer the questions without interruption, prior to any other protocol related procedures

  2. Spirometry Value; Forced Expiratory Volume at 1 Second (FEV1) [ Time Frame: Visit 3 (Baseline); Visit 6 (Week 12); Visit 8 (Week 24) ]
    Pulmonary function testing using a spirometer will be carried out at visits 3, 6 and 8 inclusive. All testing should be done in the sitting position, except for obese patients, who commonly obtain deeper inspiration when tested in the standing position. Subjects should avoid the following prior to lung function testing: Smoking within 1 hour of testing Consuming alcohol within 4 hours of testing Performing vigorous exercise within 30 minutes of testing Wearing restrictive clothing around the chest or abdomen Eating a large meal within 2 hours of testing The following medications must be withheld prior to testing, with the minimum time from last dose indicated- short acting beta agonists (6 hours), long acting beta agonists (12 hours), ipratropium bromide (12 hours), antihistamines (12 hours), long acting bronchodilator combinations (12 hours)

  3. Spirometric Values: Forced Vital Capacity (FVC) [ Time Frame: Visit 3 (Baseline); Visit 6 (Week 12); Visit 8 (Week 24) ]
    Pulmonary function testing using a spirometer will be carried out at visits 3, 6 and 8 inclusive. All testing should be done in the sitting position, except for obese patients, who commonly obtain deeper inspiration when tested in the standing position. Subjects should avoid the following prior to lung function testing: Smoking within 1 hour of testing Consuming alcohol within 4 hours of testing Performing vigorous exercise within 30 minutes of testing Wearing restrictive clothing around the chest or abdomen Eating a large meal within 2 hours of testing The following medications must be withheld prior to testing, with the minimum time from last dose indicated- short acting beta agonists (6 hours), long acting beta agonists (12 hours), ipratropium bromide (12 hours), antihistamines (12 hours), Iong acting bronchodilator combinations (12 hours)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have provided written informed consent to participate in the study in accordance with the local ethics committee regulations
  • Have a confirmed diagnosis of bronchiectasis (by HRCT) Aged 18 years or over Have chronic sputum production, defined as a greater than 45 mililitres volume produced in the 1 week prior to study entry.
  • Be able to perform reproducible spirometry
  • Be in a relatively stable disease state in the 6 weeks prior to entry, as defined by the absence of the following: respiratory exacerbations requiring hospitalisation, change in cough and/or sputum production, new or increased hemoptysis, more than 10% weight loss, use of additional antibiotic courses

Exclusion Criteria:

  • Subjects will be excluded if one or more of the following criteria occur. The subject: Is an investigator, or an immediate family member of an investigator
  • Has a confirmed diagnosis of cystic fibrosis, as evidenced by genetic analysis or a sweat test result more than 60mmol/L
  • Has a primary immunodeficiency Is a pregnant or lactating female Has had a respiratory exacerbation requiring hospitalisation or additional course of antibiotics in the 6 weeks prior to study entry
  • Has been prescribed or used oral steroids on any occasion for the 3 months prior to study entry.
  • Has been using mucolytic agents on any occasion for the 2 months prior to study entry Has active tuberculosis
  • Has an active malignancy, including melanoma (other skin carcinomas excluded)
  • Has a history of significant liver disease or insufficiency Has a significant history of drug abuse (including alcohol abuse) or mental illness Has a known intolerance or allergy to macrolides
  • Has been participating in another interventional drug study in the 3 months prior to enrolment into this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02107274


Locations
Layout table for location information
Malaysia
Respiratory Unit, Taiping Hospital
Taiping, Perak, Malaysia, 34000
Sponsors and Collaborators
Penang Hospital, Malaysia
Investigators
Layout table for investigator information
Principal Investigator: ALBERT IRUTHIARAJ ANTHONY, MBBS Penang Hospital, Malaysia

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: ALBERT IRUTHIARAJ L. ANTHONY, DR, Ministry of Health, Malaysia
ClinicalTrials.gov Identifier: NCT02107274     History of Changes
Other Study ID Numbers: NMRR-09-1075-5016
First Posted: April 8, 2014    Key Record Dates
Results First Posted: July 9, 2014
Last Update Posted: July 18, 2014
Last Verified: July 2014

Keywords provided by ALBERT IRUTHIARAJ L. ANTHONY, Ministry of Health, Malaysia:
Azithromycin
Bronchiectasis
Macrolide
Inflammation
Pulmonary

Additional relevant MeSH terms:
Layout table for MeSH terms
Bronchiectasis
Bronchial Diseases
Respiratory Tract Diseases